Revvity, Inc. (NYSE: RVTY), a provider of health science solutions and technologies, on Monday reported an increase in revenues for the second quarter of 2025.
- On a reported basis, second-quarter earnings were $0.46 per share, compared to $0.45 in the same period a year ago
- Adjusted earnings per share from continuing operations dropped to $1.18 from $1.22 a year earlier
- Second-quarter revenue increased to about $720 million from $692 million in the prior-year quarter
- Life Sciences revenues increased 5% annually to $366 million in the second quarter; Diagnostics revenue rose 3% to $354 million
- Operating income from continuing operations, on a reported basis, was $91 million, vs. $86 million in Q2 FY24
- For the full year 2025, the company raised its full-year revenue guidance to $2.84-$2.88 billion to reflect recent changes in foreign currency exchange rates; it assumes 2% to 4% organic growth
- The management also updated its adjusted earnings per share guidance to a range of $4.85 to $4.95
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Infographic: How Lennar (LEN) performed in Q4 2025
Lennar Corporation (NYSE: LEN) reported total revenues of $9.4 billion for the fourth quarter of 2025, compared to $9.9 billion reported in the same period a year ago. Net earnings
Paychex expected to report higher revenue and earnings for Q2 FY26
Paychex, Inc. (NASDAQ: PAYX), a leading provider of human capital management solutions, is undergoing an AI-driven transformation that enhances both its internal operations and client-facing services. Entering fiscal 2026, the
Signet Jewelers (SIG): A look at the progress made on Grow Brand Love
Shares of Signet Jewelers Limited (NYSE: SIG) fell over 3% on Tuesday. The stock has gained 3% year-to-date. The jewelry retailer delivered strong results for the third quarter of 2026,
